10/29/2020

Prosecutor pressed charges against a member of Orion’s Board of Directors for a suspected securities market offence – the suspected offence is not related to Orion

Prosecutor pressed charges against a member of Orion’s Board of Directors for a suspected securities market offence – the suspected offence is not related to Orion

ORION CORPORATION STOCK EXCHANGE RELEASE 29 OCTOBER 2020 at 19.00 EET             
         

Prosecutor pressed charges against a member of Orion’s Board of Directors for a suspected securities market offence – the suspected offence is not related to Orion

In accordance with the rules of the stock exchange, Orion Corporation discloses the following information:

It has come to the attention of Orion Corporation that Ari Lehtoranta, a member of Orion’s Board of Directors, has been charged in a securities markets case concerning suspected disclosure offence. According to the information Orion has, the matter is related to Mr. Lehtoranta’s operations as the CEO of Nokian Tyres Plc in 2015-2016. According to the information Orion has, Mr. Lehtoranta has denied any involvement in criminal activity.

The suspected offence is not related to Orion and Orion will not comment on the matter.

Orion Corporation

Timo Lappalainen
President and CEO
   Olli Huotari
SVP, Corporate Functions
 

                                                                                                                                   
Contact person:
Terhi Ormio, VP, Communications
tel. +358 10 426 4646

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orion.fi/en

http://www.twitter.com/OrionCorpIR

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are neurological disorders, oncology, Finnish heritage rare diseases and respiratory diseases for which Orion develops inhaled Easyhaler® pulmonary drugs. Orion's net sales in 2019 amounted to EUR 1,051 million and the company had about 3,300 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.